Degron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas.
MGDs, an emerging drug class expected to unlock the therapeutic potential of historically hard-to-drug targets, have made progress by leaps...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?